Promising drug combo targets rare sarcoma in early trial

NCT ID NCT05099666

First seen Jan 06, 2026 · Last updated May 13, 2026 · Updated 18 times

Summary

This study tests a new combination of two drugs, lurbinectedin and doxorubicin, for people with advanced leiomyosarcoma, a rare soft tissue cancer. The first part finds a safe dose, and the second part compares the combination to lurbinectedin alone to see which works better. About 62 adults with no other treatment options are taking part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED LEIOMYOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02115, United States

  • Mayo Arizona

    Phoenix, Arizona, 85054, United States

  • Mayo Jacksonville

    Jacksonville, Florida, 32224, United States

  • Mayo Rochester

    Rochester, Minnesota, 55905, United States

  • Memorial Sloan Kettering

    New York, New York, 10065, United States

Conditions

Explore the condition pages connected to this study.